ГК «Промомед» is a leader in the Russian pharmaceutical industry and actively contributes to the national drug security of the country. They specialize in the development, production, and promotion of pharmaceutical products used in various fields of medicine, including combating infections (antivirals and antibiotics), endocrinology, neurology, oncology, and general therapy. The company is known for its production of medications for COVID-19 therapy and is a leader in the production of weight regulation drugs.

They have a product portfolio of over 250 medications, with 80% of them being essential and important drugs. Additionally, the company has over 100 new medications in different stages of development and registration. With a complex research laboratory occupying 2,000 square meters, the company focuses on developing new drugs and finished pharmaceutical forms.

Their production facility, the Biochemist plant, operates in full compliance with Eurasian GMP standards and encompasses the entire pharmaceutical production process, from molecules to finished forms. Employing a team of 2,000 professionals, including over 200 medical, pharmaceutical, and chemical science candidates, the company places great importance on research and innovation in the field. With a rich history dating back to its establishment in 1952, Promomed has achieved numerous milestones and continues to make significant contributions to the pharmaceutical industry